Palatin technologies stock.

Stock Comparison Tools. A high-level overview of Palatin Technologies, Inc. (PTN) stock. Stay up to date on the latest stock price, chart, news, analysis, …GlycoMimetics Inc. -1.96%. $98.52M. PTN | Complete Palatin Technologies Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial …Common Stock Will Begin Trading on a Split-Adjusted Basis on August 31, 2022. CRANBURY, N.J., Aug. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical ...Oct 19, 2023 · CRANBURY - Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced plans to initiate a clinical study of melanocortin 4 receptor (MC4R) agonist, bremelanotide, an FDA approved product and 100% owned by Palatin, in combination with a ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system ...Earnings Date. Feb 13, 2024 - Feb 19, 2024. Forward Dividend & Yield. N/A (N/A) Ex-Dividend Date. N/A. 1y Target Est. 43.00. Find the latest Palatin Technologies, Inc. (PTN) stock quote, history, news and other vital information to …

PTN Palatin Technologies, Inc. Stock Split History (link goes to Seeking Alpha) Date Ratio Aug. 31, 2022 1:25 Sep. 27, 2010 1:10 Sep. 08, 1997 1:4 ...

Nov 14, 2023 · Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide ... 2.2200. +0.2200. +11.00%. Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript November 14, 2023 Operator: Greetings. Welcome to Palatin’s First Quarter Fiscal Year 2024 ...The Company has implemented a one-for-ten reverse stock split of its common stock, which had been authorized by the stockholders at its annual meeting held on May 13, 2010. The reverse stock split ...CRANBURY - Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of a poster entitled, Melanocortin Receptor Agonist PL9588 Reduces Intraocular Pressure in Normotensive …Jun 30, 2022 · Each share of Series B Preferred Stock and Series C Preferred Stock had a purchase price of $1.67 and is convertible into Palatin common stock at an initial conversion price of $11.25 per share. The investors in the Series B Preferred Stock and Series C Preferred Stock also received warrants to purchase up to 66,666 shares of common stock at an ...

See Palatin Technologies, Inc. (PTN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Palatin Technologies last released its earnings results on November 14th, 2023. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.07. The company earned $2.11 million during the quarter, compared to analyst estimates of $1.87 million.

Palatin Technologies Stock Earnings. The value each PTN share was expected to gain vs. the value that each PTN share actually gained. Palatin Technologies ( PTN) reported Q3 2023 earnings per share (EPS) of -$0.48, missing estimates of -$0.41 by 19.46%. In the same quarter last year, Palatin Technologies 's earnings per share (EPS) was -$0.86.Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Palatin Technologies (PTN – Research Report), with a price target of $70.00. Joseph Pantginis has given his Buy rating for ...See Palatin Technologies, Inc. (PTN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Get a real-time Palatin Technologies, Inc. (PTN) stock price quote with breaking news, financials, statistics, charts and more.Palatin Technologies, Inc is a development-stage medical technology companyinvolved in developing and commercializing products and technologies fordiagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies. Stock …The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to ...

Palatin Technologies releases earnings for Q4 on September 22. Analysts expect Palatin Technologies will report losses per share of $0.793. Go here to track Palatin Technologies stock price in ...Analyst Recommendations on Palatin Technologies, Inc. HC Wainwright Adjusts Price Target on Palatin Technologies to $70 From $5 After Reverse Stock Split, Maintains Buy Rating. 2022. MT. HC Wainwright Adjusts Palatin Technologies' Price Target to $5 From $2, Keeps Buy Rating. 2021.Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the ...Palatin Technologies, Inc. Common Stock (PTN) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00 …See Palatin Technologies, Inc. (PTN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Palatin Technologies, Inc. is a biopharmaceutical company developing medicines based on molecules that modulate the activity of the melanocortin receptor (MCr) system. The Companyâ s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need.34.99%. Get the latest Palatin Technologies, Inc. (PTN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ...

CRANBURY, N.J., Oct. 24, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) ... (or common stock equivalents in lieu thereof). Palatin has also issued in a private placement warrants to purchase up to an aggregate of 2,358,491 shares of common stock at an exercise price of $2.12 per share. The warrants are …Palatin Technologies Inc. 1.95. Delayed Data. As of 3:25pm ET. -0.06 / -2.99%. Today’s Change. 1.43. Today ||| 52-Week Range. 5.00.

Feb 23, 2022 · Palatin Technologies, Inc. (NYSE American: NYSE:PTN) is a company which I have been following for a number of years, and like many other small biotech companies, the stock has been on somewhat of ... Palatin Technologies Stock Earnings. The value each PTN share was expected to gain vs. the value that each PTN share actually gained. Palatin Technologies ( PTN) reported Q3 2023 earnings per share (EPS) of -$0.48, missing estimates of -$0.41 by 19.46%. In the same quarter last year, Palatin Technologies 's earnings per share (EPS) was -$0.86. Palatin Technologies, Inc. (PTN) stock is trading at $2.10 as of 10:09 AM on Monday, Oct 23, a decline of -$0.30, or -12.5% from the previous closing price of $2.40. The stock has traded between $1.98 and $2.16 so far today. Volume today is elevated. So far 209,989 shares have traded compared to average volume of 149,736 shares.Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system ...And in addition, common warrants to purchase up to 1,818,182 shares of Palatin common stock. Each share of common stock was offered with one accompanying common warrant for a combined offering ...Palatin Technologies, Inc. (PTN Quick Quote PTN - Free Report) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.34.This compares to loss of $0. ...13. 10. 2023. ... Palatin Technologies® is a registered trademark of Palatin Technologies, Inc. ... Palatin's common stock. What is Palatin's plan to achieve ...Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor ...Overall, these factors have prompted Michael Higgins to rate Palatin Technologies’s stock with a Buy rating. In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on ...Palatin Technologies (NYSE:PTN) said on Wednesday that its Vyleesi gross product revenue for the quarter ended March 31 increased 31% from the previous quarter and 165% on a yearly basis to $3.4M.

https://palatin.com. Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various …

22 hours ago · Palatin Technologies (NYSE:PTN) filed a prospectus related to the offer and sale by the selling stockholders of up to an aggregate of 2,476,416 shares of common stock. This prospectus is not an ...

Palatin Technologies Inc PTN Morningstar Rating Stock XASE Rating as of Nov 23, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns …Nov 30, 2023 · According to the issued ratings of 1 analysts in the last year, the consensus rating for Palatin Technologies stock is Buy based on the current 1 buy rating for PTN. The average twelve-month price prediction for Palatin Technologies is $70.00 with a high price target of $70.00 and a low price target of $70.00. Learn more on PTN's analyst rating ... The Palatin Technologies stock prediction results are shown below and presented as a graph, table and text information. Palatin Technologies stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Palatin Technologies analysts is $ 43. Today 200 Day Moving Average …34.99%. Get the latest Palatin Technologies, Inc. (PTN) real-time quote, historical performance, charts, and other financial information to help you make more informed …Earnings Date. Feb 13, 2024 - Feb 19, 2024. Forward Dividend & Yield. N/A (N/A) Ex-Dividend Date. N/A. 1y Target Est. 43.00. Find the latest Palatin Technologies, Inc. (PTN) stock quote, history, news and other vital information to …The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to ...Research Palatin Technologies' (LSE:0KF3) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more. Dashboard Markets Discover Watchlist Portfolios Screener. Stocks / United Kingdom / Pharmaceuticals & Biotech; Palatin Technologies LSE:0KF3 Stock Report. Last Price.See Palatin Technologies, Inc. (PTN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The latest closing stock price for Palatin Technologies as of December 01, 2023 is 2.22. The all-time high Palatin Technologies stock closing price was 2407.50 on October 17, 1997. The Palatin Technologies 52-week high stock price is 5.00, which is 125.2% above the current share price.PTN | Complete Palatin Technologies Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Analyst Recommendations on Palatin Technologies, Inc. HC Wainwright Adjusts Price Target on Palatin Technologies to $70 From $5 After Reverse Stock Split, Maintains Buy Rating. 2022. MT. HC Wainwright Adjusts Palatin Technologies' Price Target to $5 From $2, Keeps Buy Rating. 2021.Good morning, and welcome to the Palatin first quarter fiscal year 2024 call. I'm Dr. Carl Spana, the CEO and President of Palatin. With me on the call today is Steve Wills, Palatin's Executive ...Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system ...Dec 1, 2023 · Palatin Technologies last issued its earnings results on November 14th, 2023. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.07. The firm earned $2.11 million during the quarter, compared to analyst estimates of $1.87 million. Instagram:https://instagram. best way to track your investmentsgm cruise stocksuze orman bookbest asset management firms The latest Palatin Technologies stock prices, stock quotes, news, and PTN history to help you invest and trade smarter.According to 1 stock analyst, the 12-month stock price forecast for PTN stock stock is $70, which predicts an increase of 3,417.59%. On average, analysts rate PTN stock stock as a strong buy. ria firmsita etf holdings Earnings Date. Feb 13, 2024 - Feb 19, 2024. Forward Dividend & Yield. N/A (N/A) Ex-Dividend Date. N/A. 1y Target Est. 43.00. Find the latest Palatin Technologies, Inc. (PTN) stock quote, history, news and other vital information to …Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women ... tsly ex dividend date And in addition, common warrants to purchase up to 1,818,182 shares of Palatin common stock. Each share of common stock was offered with one accompanying common warrant for a combined offering ...Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women …